Danish Pharma Nord Nordisk is looking to reduce the weight of hard drugs amid the shutdown
FOX Business ‘Lydia Hu reports on the latest news from the pharmaceutical industry as the US health crisis hits a new record.
“Something is rotten in the state of Denmark,” as Hamlet says in Shakespeare’s time. It was true then, and it is true today.
While senate Democrats are holding government hostages in their ridiculous shutdown so they can provide free health care to illegal aliens, Federal services are not being fulfilled. Some foreign companies are trying to exploit this to keep their profit as much as possible.
Novo Nordisk, a biotech company in Denmark, is trying to intervene in the American pharmaceutical market to suppress competition, protect its dominant market position, and stop competition from drugs that have lost weight from entering the market.
Weight loss could be just a pill away, the study of new drugs suggests
Novo, maker of Ozempic and Wegovy, has significant market share in the GLP1 drug space, which has revolutionized obesity treatment. Given the growing burden of obesity-related diseases, this is a huge industry, with the potential to generate billions in revenue and the potential to help many Americans. Recently, Novo announced plans to launch a new New York City-based Metsera, which has an advanced weight loss drug in its pipeline.
Injection pens for WOGH weight loss treatment, Produced by Novo Nordisk A/S, on display during a press conference in Mumbai, India, 2025. Novo Nordisk said it will sell its blockbuster weight loss treatment (Dhiraj Singh/Bloomberg via Getty Images/Getty Images)
Novo already holds a dominant market share of the medical weight loss market. If the company were to acquire Metsca, its position would be strengthened. This means less competition, higher prices, less access, more obesity, and poorer health.
In addition, such acquisitions require federal review. First, because of antitrust concerns, the Securities and Exchange Commission should review this fee. Stat Trump Trump All-Star FTC Chairman Andrew Ferguson has served as a health care competitor across America. In addition, because Novo is a foreign company, the Committee on Foreign Investment in the United States (CFIS) may need to take action.
Could it be that a GLP-1 weight loss drug like Ozempic is becoming a ‘do-it-all drug’?
Given the current government shutdown, you may have planned this to avoid the perception that human control is renewed and possibly illegal.
Novo’s strategy for Shady is to make the first payment for metsera shares. That can effectively deliver Novo Control Control of Metsera and undue influence on the company before the purchase and even a controlled review. While the Danish company bought an American does not represent an obvious threat to national security, allowing Novo to find a promising company backed by biotech that could lead to the loss of American jobs could lead to other countries.
Government agencies like the FTC and CFIUS are there to monitor this kind of business activity for very good reasons – that they will be able to do it if they don’t shut down the government of the Senate Democrats for too long. Until Senate Democrats end this executive order, so the federal government can do its due diligence, such a deal should not pass.
Still the health of the three weight loss pills for weight loss. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk / UCG / Universal Pictures Group via Getty Images) (Michael Siluk / UCG / Urfery Images Group via Getty Images / Getty Images)
In addition, Novo has shown a great lack of good faith with President Trump’s Voter-adgesed shitch directed directly at the country’s polls. President Trump has made it a priority to increase health care and lower drug prices for all Americans, but especially those who can’t afford it. FTC Chairman Andrew Ferguson is leading the charge to ensure that our health markets deliver fair prices and better outcomes for patients and other consumers. When President Trump announced his most favored nation (MFN) to bring drug prices, thankfully, many American pharmaceutical companies answered the call.
This deal shows the importance of President Trump’s America first focus on foreign business. This is not jingoism or nationalism or any other part – the enemies of the President like to throw it at us. America first does not mean America only. It means if the agreement is bad for us, we should not do it. This is basically correct.
Novo plays games with poor handling. President Trump and Chairman Ferguson should not stand by while a foreign company tries to prevent important government recognition, certainly not when it includes promoting the control of an important category of new drugs. If Novo moves forward with its metsera bid, it should attract a lot of attention from FTC Chairman Andrew Ferguson, President of Prongual Trump Competition Watchdog and champion.
